J&J Q3 profit drops 7% on higher research, production costs

The maker of Tylenol, baby shampoo and prescription drugs said Tuesday that its net income was US$2.97 billion, or US$1.05 per share. That's down from US$3.2 billion, of US$1.15 per share, in 2011's third quarter.

Excluding one-time charges for research, the acquisition and litigation, earnings were US$3.5 billion, or US$1.25 per share.

Revenue rose 6.5 percent to US$17.05 billion, boosted nearly 6 percent by sales from Synthes Inc., a maker of surgical trauma equipment and orthopedic implants that J&J bought for US$19.7 billion in June.

The results beat Wall Street expectations for earnings of US$1.21 per share on revenue of US$17.01 billion.

SHARE CLOSE
Blogger		Google+
Live Journal		Plurk
Stumble Upon

Tweet

	PREVIOUS ARTICLE
	Markets in Asia boosted on higher eurozone confidence

NEXT ARTICLE
Goldman Sachs' earnings up but caution rules

Write a Comment

Terms

Enter your comments - 3000 characters max

Type in image code

 Receive China Post promos
 Respond to this email

Submit